Capricor Therapeutics Inc
CAPR
View Detailed Chart
24.720USD
+1.690+7.34%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.34%
5 Days
+12.93%
1 Month
-5.40%
6 Months
+219.38%
Year to Date
-14.35%
1 Year
+72.51%
View Detailed Chart
TradingKey Stock Score of Capricor Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Capricor Therapeutics Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 50.80.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Capricor Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Capricor Therapeutics Inc Highlights
StrengthsRisks
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 772.85% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 22.27M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 22.27M.
Undervalued
The company’s latest PE is -14.14, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.69M shares, increasing 0.05% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.78K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.09.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
50.800
Target Price
+120.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Capricor Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Capricor Therapeutics Inc Info
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Ticker SymbolCAPR
CompanyCapricor Therapeutics Inc
CEOMarban (Linda)
Websitehttps://capricor.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68174.180
-1795.950 (-2.57%)
282.580
+22.390 (+8.61%)
2023.010
-28.720 (-1.40%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
